| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2011 | CA2771539A1 Pharmaceutical compositions with tetrabenzine |
| 02/17/2011 | CA2771203A1 Treatment of bdnf-related disorders using laquinimod |
| 02/17/2011 | CA2771083A1 Selective sphingosine-1-phosphate receptor antagonists |
| 02/17/2011 | CA2771056A1 Fgf receptor-activating n-acyl octasaccharides, preparation thereof, and therapeutic use thereof |
| 02/17/2011 | CA2771055A1 Fgf receptor-activating n-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof |
| 02/17/2011 | CA2771053A1 Floating microgranules |
| 02/17/2011 | CA2770896A1 Cathepsin c inhibitors |
| 02/17/2011 | CA2770894A1 Isothiozoles for treating conditions of the eye |
| 02/17/2011 | CA2770873A1 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| 02/17/2011 | CA2770793A1 Azetidinone compounds and medical use thereof |
| 02/17/2011 | CA2770737A1 Antibodies against human respiratory syncytial virus (rsv) and methods of use |
| 02/17/2011 | CA2770724A1 Compounds and methods of use thereof |
| 02/17/2011 | CA2770698A1 Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions |
| 02/17/2011 | CA2770683A1 Vitamin d3 and analogs thereof for treating alopecia |
| 02/17/2011 | CA2770583A1 Pharmaceutical composition for relieving pain |
| 02/17/2011 | CA2770582A1 Steroid solvates |
| 02/17/2011 | CA2770578A1 Dry powder inhaler formulations |
| 02/17/2011 | CA2770494A1 Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases |
| 02/17/2011 | CA2770441A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| 02/17/2011 | CA2770403A1 Intravenous formulations of neurokinin-1 antagonists |
| 02/17/2011 | CA2770397A1 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
| 02/17/2011 | CA2770320A1 Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof |
| 02/17/2011 | CA2770262A1 Pharmaceutical composition including a dha ester to be parenterally administered |
| 02/17/2011 | CA2770211A1 Methods for iontophoretically treating nausea and migraine |
| 02/17/2011 | CA2770116A1 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| 02/17/2011 | CA2770104A1 Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| 02/17/2011 | CA2769929A1 Ophthalmic drug delivery system containing phospholipid and cholesterol |
| 02/17/2011 | CA2769847A1 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| 02/17/2011 | CA2769820A1 Method for making 3.alpha.-hydroxy, 3.beta.- methyl-5.alpha.-pregnan-20-one (ganaxolone) |
| 02/17/2011 | CA2769803A1 Stabilised particles comprising 5-methyl-(6s)-tetrahydrofolate |
| 02/17/2011 | CA2769764A1 Combination of proantocycidins such as pycnogenol or grape seeds and centella asiatica for the treatment of cardiovascular disorders such as atherosclerosis |
| 02/17/2011 | CA2769695A1 Pharmaceutical composition and administrations thereof |
| 02/17/2011 | CA2769674A1 Combination therapy of an afucosylated cd20 antibody with bendamustine |
| 02/17/2011 | CA2769616A1 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein |
| 02/17/2011 | CA2769595A1 Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
| 02/17/2011 | CA2769551A1 New macrolides and their use |
| 02/17/2011 | CA2768877A1 Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid |
| 02/17/2011 | CA2768749A1 Inhibitors of jnk |
| 02/17/2011 | CA2764236A1 Compositions and methods for treating fungal infection of the nail |
| 02/17/2011 | CA2760516A1 Pyrido[4,3-b]indoles and methods of use |
| 02/16/2011 | EP2284535A1 Low molecular weight heparins |
| 02/16/2011 | EP2284269A2 Antisense design |
| 02/16/2011 | EP2284268A2 Conserved HBV and HCV sequences useful for gene silencing |
| 02/16/2011 | EP2284266A2 Functional and hyperfunctional sirna |
| 02/16/2011 | EP2284264A1 Induction of exon skipping in eukaryotic cells |
| 02/16/2011 | EP2284210A1 Charge conversional ternary polyplex |
| 02/16/2011 | EP2284209A1 Polymer conjugate of folic acid or folic acid derivative |
| 02/16/2011 | EP2284174A1 Intermediates for the preparation of benzoxazine derivatives and process for their preparation |
| 02/16/2011 | EP2284172A1 Immunomodulating heterocyclic compounds |
| 02/16/2011 | EP2284171A1 Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types |
| 02/16/2011 | EP2284170A1 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 02/16/2011 | EP2284169A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders |
| 02/16/2011 | EP2284168A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 02/16/2011 | EP2284167A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 02/16/2011 | EP2284164A2 Substituted tetracycline compounds |
| 02/16/2011 | EP2284160A1 Pyrimidine derivative having cell-protecting activity and use thereof |
| 02/16/2011 | EP2284159A1 5-hydroxypyrimidine-4-carboxamide compound |
| 02/16/2011 | EP2284158A1 Quinoline compounds, pharmaceutical compositions, preparation methods and uses thereof |
| 02/16/2011 | EP2284157A1 Quinolines useful in treating cardiovascular disease |
| 02/16/2011 | EP2284156A2 Substituted tetracycline compounds |
| 02/16/2011 | EP2284155A2 Substituted tetracycline compounds |
| 02/16/2011 | EP2284154A1 Antitumor 1,2-diphenylpyrrole compounds and their preparation process |
| 02/16/2011 | EP2284153A2 Substituted tetracycline compounds |
| 02/16/2011 | EP2284152A2 Substituted tetracycline compounds |
| 02/16/2011 | EP2284151A2 Substituted tetracycline compounds |
| 02/16/2011 | EP2284150A2 Substituted tetracycline compounds |
| 02/16/2011 | EP2284149A1 Selective androgen receptor modulators and methods of use thereof |
| 02/16/2011 | EP2283898A1 Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 02/16/2011 | EP2283865A1 Method of increasing testosterone and related steroid concentrations in women |
| 02/16/2011 | EP2283864A1 Liquid dosage compositions fo stable nanoparticulate active agents |
| 02/16/2011 | EP2283863A1 Model and method for angiogenesis inhibition |
| 02/16/2011 | EP2283862A1 Antitumor agent |
| 02/16/2011 | EP2283850A1 Pharmaceutical compositions and methods for peptide treatment |
| 02/16/2011 | EP2283846A1 miRNA compounds for treatment of prostate carcinoma |
| 02/16/2011 | EP2283845A1 Sustained release drug delivery system containing codrugs |
| 02/16/2011 | EP2283844A1 A solid pharmaceutical dosage formulation comprising lopinavir |
| 02/16/2011 | EP2283843A2 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
| 02/16/2011 | EP2283842A1 Tamper-resitant oral opioid agonist formulations |
| 02/16/2011 | EP2283841A1 Selective serotonin receptor inverse agonists as therapeutics for disease |
| 02/16/2011 | EP2283840A1 The use of mirtazapine for the treatment of sleep disorders. |
| 02/16/2011 | EP2283839A1 Polyunsaturated hydroxylated molecule having an eze geometry and its use in therapy |
| 02/16/2011 | EP2283838A2 Docosahexaenoic acid for treating subclinical inflammation |
| 02/16/2011 | EP2283837A2 Docosahexaenoic acid for treating subclinical inflammation |
| 02/16/2011 | EP2283836A1 Anti-inflammatory creatine composition comprising a cetylated fatty acid |
| 02/16/2011 | EP2283835A2 Method and preparation for treating metabolic stress |
| 02/16/2011 | EP2283834A2 Therapeutic compositions comprising ketone bodies or their precursors |
| 02/16/2011 | EP2283833A2 Amines and amides for the treatment of diseases |
| 02/16/2011 | EP2283832A1 Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
| 02/16/2011 | EP2283831A2 Biomakers for pre-selection of patients for anti-IGF1R therapy |
| 02/16/2011 | EP2283829A1 Controlled release hydrocodone formulations |
| 02/16/2011 | EP2283828A1 Pharmaceutical compositions |
| 02/16/2011 | EP2283827A1 Controlled release preparation |
| 02/16/2011 | EP2283826A2 Galenic formulations of organic compounds |
| 02/16/2011 | EP2283825A1 Enteric solid oral dosage form of a bisphosphonate containing a chelating agent |
| 02/16/2011 | EP2283824A1 Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin |
| 02/16/2011 | EP2283822A2 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/16/2011 | EP2283821A1 Preparation of biodegradable microparticles containing a biologically active agent |
| 02/16/2011 | EP2283820A1 Residual solvent extraction method and microparticles produced thereby |
| 02/16/2011 | EP2283818A1 Method of making particles for use in a pharmaceutical composition |
| 02/16/2011 | EP2283817A1 Method of making particles for use in a pharmaceutical composition |